GGrantIndex
Sort

64,565 grants matching drug discovery

Transformational next generation high affinity trispecific fab protein to address unmet needs in Ophthalmology

$933,533
Li Xu · Revopsis Therapeutics, Inc. · R44 · FY2024 · EY

Transformational next generation high affinity trispecific fab protein to address unmet needs in Ophthalmology

$933,533
Li Xu · Revopsis Therapeutics, Inc. · R44 · FY2025 · EY

Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer's Therapeutics

$933,415
Paul Gregor · Gismo Therapeutics, Inc. · R44 · FY2017 · AG

Split-Maze Discovery of Antiobesity Drugs

$933,335
Novasite Pharmaceuticals, Inc. · R44 · FY2003 · DK

RNA: Structure, Biophysics and Physiology

$933,275
Adrian Ferre-D'amare · National Heart, Lung, And Blood Institute · ZIA · FY2012 · HL

Specification and Function of Tissue Resident and Recruited Macrophages in Cardiac Remodeling and Heart Failure

$933,000
Kory J. Lavine · Washington University · R35 · FY2025 · HL

The Development of a Web-based Data Retrieval System for HIV Therapy Guidance

$932,999
Christos J Petropoulos · Monogram Biosciences, Inc. · R44 · FY2008 · AI

New Ways of Targeting K-Ras

$932,874
Frank Patrick McCormick · University Of California, San Francisco · R35 · FY2016 · CA

Novel Antibiotics from Unculturable Actinomycetes

$932,873
Novobiotic Pharmaceuticals, Llc · R01 · FY2005 · AI

Plasmonic Scattering Microscopy for high-throughput in-situ quantification of molecular binding kinetics on single cells

$932,810
Nguyen Ly · Biosensing Instrument, Inc. · R42 · FY2025 · GM

Systematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbation

$932,722
Haian Fu · Emory University · U01 · FY2020 · CA

Development of an inhibitory oligonucleotide for the treatment of lupus

$932,510
Robert L Coffman · Dynavax Technologies Corporation · R44 · FY2009 · AI

Systematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbation

$932,391
Haian Fu · Emory University · U01 · FY2021 · CA

DNA Topoisomerases as Target of Action of Anticancer Drugs

$932,263
Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment

$931,980
Sanford D Markowitz · Case Western Reserve University · R35 · FY2022 · CA

Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment

$931,980
Sanford D Markowitz · Case Western Reserve University · R35 · FY2023 · CA

HIV RNase H natural product inhibitors

$931,781
Michael A Parniak · University Of Pittsburgh At Pittsburgh · U19 · FY2007 · AI

Discovery, Structural Studies and Biosynthesis of Biologically Active Natural Products and Natural Product-Like Inhibitors

$931,691
Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK

Discovery of Natural Products and Natural Product-Like Inhibitors

$931,691
Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK

Discovery of Natural Products and Natural Product-Like Inhibitors

$931,690
Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK

Synthesis of non-GMP Small Molecules

$931,000
Dumitru Ionescu · Ash Stevens, Inc. · N02 · FY2010 · CA

Core B Medicinal Chemistry

$930,949
Joel Stephen Freundlich · Hackensack University Medical Center · U19 · FY2022 · AI

Core C Pharmacology

$930,948
Vidmantas Petraitis · Hackensack University Medical Center · U19 · FY2023 · AI

Genomic Medicine Implementation: The Personalized Medicine Program

$930,567
Julie A. Johnson · University Of Florida · U01 · FY2017 · HG

Defining and Manipulating Epigenomic Regulators in Endogenous Systems

$930,474
Jordan Leslie Meier · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA